<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0">
<channel>
<title>Inbox Robot: Ophthalmics News</title>
<link>http://www.inboxrobot.com/news/ophthalmics</link>
<description>Constantly updated news and information about a variety of topics.</description><item>
<title>Nitric Oxide Monitoring of Little Benefit for Kids&#39; Asthma</title>
<link>http://www.inboxrobot.com/news.php?fid=207372885</link>
<pubDate>9 Jan 2009 20:19 GMT</pubDate>
<description>
...  fibrillation and hemodynamically unstable ventricular tachycardia in patients refractory to other therapy. Latisse (bimatoprost ophthalmic) is a prostamide indicated for the treatment of hypotrichosis (or reduced amount of hair)  ...
</description>
</item><item>
<title>Officials Still Seek Source of Salmonella Outbreak</title>
<link>http://www.inboxrobot.com/news.php?fid=207372884</link>
<pubDate>9 Jan 2009 20:19 GMT</pubDate>
<description>
...  fibrillation and hemodynamically unstable ventricular tachycardia in patients refractory to other therapy. Latisse (bimatoprost ophthalmic) is a prostamide indicated for the treatment of hypotrichosis (or reduced amount of hair)  ...
</description>
</item><item>
<title>BRIEF-Lazard capital downgrades Allergan to hold</title>
<link>http://www.inboxrobot.com/news.php?fid=207368304</link>
<pubDate>9 Jan 2009 19:39 GMT</pubDate>
<description>
...  * Lazard capital says downgrade based on concerns of further cosmetic declines and difficult ophthalmic comps * Lazard capital cuts Allergan 2009 EPS estimate to $2.72 from $2.77 ((Bangalore  ...
</description>
</item><item>
<title>Childhood Leukemia Subtype Resists Treatment</title>
<link>http://www.inboxrobot.com/news.php?fid=207360707</link>
<pubDate>9 Jan 2009 18:57 GMT</pubDate>
<description>
...  fibrillation and hemodynamically unstable ventricular tachycardia in patients refractory to other therapy. Latisse (bimatoprost ophthalmic) is a prostamide indicated for the treatment of hypotrichosis (or reduced amount of hair)  ...
</description>
</item><item>
<title>Clinical Trials Update: Jan. 9, 2009</title>
<link>http://www.inboxrobot.com/news.php?fid=207360704</link>
<pubDate>9 Jan 2009 18:57 GMT</pubDate>
<description>
...  fibrillation and hemodynamically unstable ventricular tachycardia in patients refractory to other therapy. Latisse (bimatoprost ophthalmic) is a prostamide indicated for the treatment of hypotrichosis (or reduced amount of hair)  ...
</description>
</item><item>
<title>Drug Pipeline Progress - December 22-28</title>
<link>http://www.inboxrobot.com/news.php?fid=207328366</link>
<pubDate>9 Jan 2009 16:09 GMT</pubDate>
<description>
...  doses of T-62 and placebo utilizing a parallel design.  FDA approved LATISSE (bimatoprost ophthalmic solution) 0.03% as a novel treatment for hypotrichosis of the eyelashes, December 26, 2008  ...
</description>
</item><item>
<title>Parents Not Best Barometer of Kid&#39;s Eating, Exercise Habits</title>
<link>http://www.inboxrobot.com/news.php?fid=207327802</link>
<pubDate>9 Jan 2009 16:09 GMT</pubDate>
<description>
...  fibrillation and hemodynamically unstable ventricular tachycardia in patients refractory to other therapy. Latisse (bimatoprost ophthalmic) is a prostamide indicated for the treatment of hypotrichosis (or reduced amount of hair)  ...
</description>
</item><item>
<title>Health Tip: See Your Doctor Before Pregnancy</title>
<link>http://www.inboxrobot.com/news.php?fid=207327801</link>
<pubDate>9 Jan 2009 16:09 GMT</pubDate>
<description>
...  fibrillation and hemodynamically unstable ventricular tachycardia in patients refractory to other therapy. Latisse (bimatoprost ophthalmic) is a prostamide indicated for the treatment of hypotrichosis (or reduced amount of hair)  ...
</description>
</item><item>
<title>Cotton Tree</title>
<link>http://www.inboxrobot.com/news.php?fid=207314883</link>
<pubDate>9 Jan 2009 14:38 GMT</pubDate>
<description>
...  left. The suburb has also attracted a number of doctors and medical specialists, including optometrists, physiotherapists, chiropractors and dentists. Youll find the Maroochy RSL at the top end of  ...
</description>
</item><item>
<title>Nestled on the banks of the Maroochy River, where the fresh water winds its way to meet the ocean, the beachside hamlet of Cotton Tree has long been a popular spot for holiday-makers.</title>
<link>http://www.inboxrobot.com/news.php?fid=207314882</link>
<pubDate>9 Jan 2009 14:38 GMT</pubDate>
<description>
...  left. The suburb has also attracted a number of doctors and medical specialists, including optometrists, physiotherapists, chiropractors and dentists. Youll find the Maroochy RSL at the top end of  ...
</description>
</item><item>
<title>He had music drilled into him from an early age</title>
<link>http://www.inboxrobot.com/news.php?fid=207311674</link>
<pubDate>9 Jan 2009 14:32 GMT</pubDate>
<description>
...  get together with Joe Giordano, an orthodontist in Lawrence, and Dr. David Metsch, an optometrist from North Andover. We play out quite a bit. We decided at one point  ...
</description>
</item><item>
<title>Inflammatory Factors May be Key to Controlling Diabetic Macular Edema</title>
<link>http://www.inboxrobot.com/news.php?fid=207308633</link>
<pubDate>9 Jan 2009 13:51 GMT</pubDate>
<description>
...  a world-wide diabetes epidemic that is motivating ophthalmic research around the globe. Hideharu Funatsu, MD,  ...  provided by the three &quot;O&#39;s&quot; - opticians, optometrists and ophthalmologists. It is the ophthalmologist, or  ...
</description>
</item><item>
<title>RegeneRx Reports Phase II Pressure Ulcer Trial Results</title>
<link>http://www.inboxrobot.com/news.php?fid=207307536</link>
<pubDate>9 Jan 2009 13:50 GMT</pubDate>
<description>
...  repair. Currently, RegeneRx is developing three product candidates, RGN-137, RGN-259 and RGN-352 for dermal, ophthalmic, and cardiovascular tissue repair, respectively. RegeneRx is also developing RGN-457 for use in pulmonary  ...
</description>
</item><item>
<title>--&gt; EyeGate Pharma Receives Orphan Drug Designation for Corneal Graft Rejection From U.S. FDA</title>
<link>http://www.inboxrobot.com/news.php?fid=207306884</link>
<pubDate>9 Jan 2009 13:46 GMT</pubDate>
<description>
...  deliver drugs to both the front and back of the eye. EGP-437, dexemethasone phosphate ophthalmic solution (ultimately releasing dexamethasone), is delivered via the EyeGate II, which consists of an  ...
</description>
</item><item>
<title>EyeGate Pharma Receives Orphan Drug Designation for Corneal Graft Rejection From U.S. FDA</title>
<link>http://www.inboxrobot.com/news.php?fid=207304365</link>
<pubDate>9 Jan 2009 13:42 GMT</pubDate>
<description>
...  deliver drugs to both the front and back of the eye. EGP-437, dexemethasone phosphate ophthalmic solution (ultimately releasing dexamethasone), is delivered via the EyeGate II, which consists of an  ...
</description>
</item></channel>
</rss>
